<DOC>
	<DOCNO>NCT00334815</DOCNO>
	<brief_summary>This clinical trial study combination chemotherapy , radiation therapy , bevacizumab treat patient newly diagnose stage III non-small cell lung cancer remove surgery . Drugs use chemotherapy , cisplatin , etoposide , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving one drug ( combination chemotherapy ) together radiation therapy bevacizumab may kill tumor cell .</brief_summary>
	<brief_title>Combination Chemotherapy , Radiation Therapy , Bevacizumab Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine frequency severity toxic effect induction therapy comprise cisplatin , etoposide , radiotherapy without bevacizumab follow consolidation therapy comprise docetaxel bevacizumab , term grade 4 5 hemorrhage , patient newly diagnose , unresectable , stage III non-small cell lung cancer . SECONDARY OBJECTIVES : I . Determine progression-free overall survival patient treat regimen . II . Determine response ( confirm , unconfirmed , partial , complete ) patient measurable disease treat regimen . OUTLINE : This pilot , multicenter study . Patients stratify accord risk ( high* vs low ) . NOTE : *High-risk stratum close accrual 2/20/09 . INDUCTION THERAPY : Patients stratum assign 1 3 sequential treatment group . GROUP 1 : Patients receive cisplatin intravenously ( IV ) 1 hour day 1 , 8 , 29 , 36 etoposide IV 1 hour day 1-5 29-33 . Patients undergo concurrent thoracic radiotherapy daily day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 , 43-47 . GROUP 2 : Patients receive cisplatin , etoposide , thoracic radiotherapy group 1 . Patients also receive bevacizumab IV 30-90 minute day 15 , 36 , 57 . GROUP 3 : Patients receive cisplatin , etoposide , thoracic radiotherapy group 1 . Patients also receive bevacizumab IV 30-90 minute day 1 , 22 , 43 . CONSOLIDATION CHEMOTHERAPY : Beginning 3-6 week completion induction therapy , patient receive consolidation chemotherapy comprise docetaxel IV 1 hour bevacizumab IV 30-90 minute day 1 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 2 continue blood count recover OR pegfilgrastim SC day 2 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 4 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Adenocarcinoma , Bronchiolo-Alveolar</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically cytologically confirm single , primary , bronchogenic , nonsmall cell lung cancer ( NSCLC ) Newly diagnose disease Unresectable disease No 1 parenchymal lesion opposite side lung Meets 1 follow stage criterion : Stage IIIA ( N2 ) disease meeting follow criterion : N2 mediastinal lymph node must multiple and/or bulky CT scan xray patient candidate induction chemotherapy chemoradiotherapy follow surgical resection N2 status must document ≥ 1 follow method : Histologically cytologically confirm N2 disease exploratory thoracotomy , thoracoscopy , mediastinoscopy , mediastinotomy , Chamberlain procedure , Wang needle biopsy ( WNB ) , fine needle aspiration ( FNA ) bronchoscopic CT guidance , method Node positive fludeoxyglucosepositron emission tomography ( FDGPET ) scan Nodes &gt; 3 cm CT scan Paralyzed leave true vocal cord separate leave lung primary distinct anteriorposterior window node CT scan Stage IIIB disease meeting ≥ 1 follow criterion : Histologically radiographically confirm positive N3 nodes* , document ≥ 1 follow method : FNA , core needle biopsy ( CNB ) , excisional biopsy supraclavicular N3 node Biopsy contralateral mediastinal N3 node mediastinoscopy , mediastinotomy , thoracotomy FNA , CNB , WNB CT bronchoscopic fluoroscopic guidance enlarge contralateral N3 mediastinal nod Contralateral mediastinal node &gt; 3 cm CT scan Node positivity FDGPET scan Rightsided primary paralyze left true vocal cord T4 lesion size invade mediastinum , heart , great vessel , trachea , esophagus , vertebral body , carina , document ≥ 1 follow method : Written documentation type T4 extent patient prior exploratory thoracotomy thoracoscopy T4 involvement trachea carina direct bronchoscopic visualization T4 involvement heart , esophagus , aorta , vertebral body CT scan , MRI , transesophageal ultrasound T4 involvement mediastinum CT scan MRI , absence organ involvement , soft tissue extension directly mediastinal space** Meets 1 follow risk criterion : Low risk disease , meet follow criterion : Nonsquamous cell NSCLC , include adenocarcinoma , bronchoalveolar cell carcinoma , large cell carcinoma If mixed histology , squamous cell carcinoma component must &lt; 50 % Histology cytology involve mediastinal supraclavicular lymph node allow separate distal primary lesion clearly evident radiograph ( i.e. , second biopsy require ) No primary tumor cavitation and/or tumor within 1 cm major vessel No hemoptysis ( i.e. , bright red blood ≥ ½ teaspoon ) past 28 day Highrisk* disease , meet ≥ 1 follow criterion : Squamous cell NSCLC If mixed histology , squamous cell component must ≥ 50 % Tumor histology cavitation locate within 1 cm major vessel No aortic involvement Any histology hemoptysis ( i.e. , bright red blood ≥ ½ teaspoon ) within past 28 day Measurable nonmeasurable disease CT scan MRI Pleural effusion , ascites , laboratory parameter acceptable evidence disease No pleural effusion except small pleural effusion visible CT scan MRI alone No pericardial effusion No metastatic disease involve contralateral chest , liver , adrenal confirm CT scan upper abdomen chest CT scan complete liver adrenal report Patients must offer participation SWOGS9925 ( Lung Cancer Specimen Repository Protocol ) No brain metastasis CT scan MRI No evidence cavitation Creatinine normal Creatinine clearance ≥ 50 mL/min FEV_1 ≥ 2.0 liter OR predict FEV_1 contralateral lung &gt; 800 mL Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Urine protein : creatinine ratio ≤ 0.5 urinalysis OR urine protein &lt; 1,000 mg 24hour urine collection INR &lt; 1.5 Zubrod performance status 01 No sensory neuropathy &gt; grade 1 No cerebrovascular accident within past 6 month No myocardial infarction unstable angina within past 6 month No uncontrolled hypertension No New York Heart Association class IIIV congestive heart failure No serious cardiac arrhythmia require medication No clinically significant peripheral vascular disease No evidence bleed diathesis coagulopathy No pathologic condition lung cancer carry high risk bleed No known hypersensitivity Chinese hamster ovary cell product recombinant human antibodies No serious , nonhealing wound , ulcer , bone fracture No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year Not pregnant nursing No nursing ≥ 6 month last dose bevacizumab Negative pregnancy test Fertile patient must use effective contraception ≥ 6 month last dose bevacizumab Must pretreatment simulation demonstrate V20 ≤ 35 % plan radiation dose 6,480 cGy No prior surgical resection Prior exploratory thoracotomy , mediastinoscopy , excisional biopsy , similar surgery allow diagnosing , stag , determine potential resectability lung tumor No prior chemotherapy radiotherapy lung cancer No prior radiotherapy neck thorax At least 4 week since prior thoracic major surgery ( exclude mediastinoscopy ) recover More 7 day since prior FNA , CNB , mediastinoscopy No concurrent anticancer therapy , include chemotherapy , radiotherapy , biologic agent No concurrent investigational drug No concurrent major surgical procedure No concurrent fulldose anticoagulant ( e.g. , lowmolecular weight unfractionated heparin warfarin ) Lowdose warfarin ( i.e. , 1 mg ) allow prevent clot infusaport central line No concurrent brachytherapy , radiopharmaceutical , high linear energy transfer radiation ( i.e. , fast neutron ) , particle therapy ( i.e. , proton , carbon , helium ) , and/or alter fractionation scheme No concurrent intensitymodulated radiotherapy No concurrent prophylactic contralateral hilar supraclavicular lymph node radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>